Expanded Access Program With Nivolumab in Combination With Ipilimumab in Patients With Tumors Unable to be Removed by Surgery or Metastatic Melanoma
NCT02186249 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS
Last updated 2017-02-08
Summary
The purpose of this study is to provide treatment with nivolumab in combination with ipilimumab to subjects who are anti-(CTLA)-4 and anti-PD-1 treatment-naive and have unresectable or metastatic melanoma.
Conditions
- Malignant Melanoma
Interventions
- DRUG
- DRUG
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Bristol-Myers Squibb · Bristol-Myers Squibb
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
Countries
- United States
- Canada
Study Locations
More Related Trials
-
An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread
NCT02658890 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma
NCT02714218 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Nivolumab (BMS-936558) Plus Ipilimumab Compared With Ipilimumab Alone in the Treatment of Previously Untreated, Unresectable, or Metastatic Melanoma
NCT01927419 ·Status: COMPLETED ·Phase: PHASE2
-
Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Nivolumab or Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Observation Compared With Adjuvant Nivolumab in Treatment-Naive High-risk Melanoma Participants
NCT04495010 ·Status: WITHDRAWN ·Phase: PHASE2
-
A Clinical Trial: Adjuvant Low-dose Ipilimumab + Nivolumab After Resection of Melanoma Macrometastases
NCT02941744 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Pilot Study of the Safety/Efficacy of Combination Checkpoint Blockade + External Beam Radiotherapy in Stage IV Melanoma
NCT02659540 ·Status: COMPLETED ·Phase: PHASE1
-
An Investigational Immuno-therapy Study to Evaluate Safety and Effectiveness in Patients With Melanoma That Has Spread to the Brain, Treated With Nivolumab in Combination With Ipilimumab, Followed by Nivolumab by Itself
NCT02320058 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Intratumoral Injection of Interleukin-2 and Ipilimumab in Patients With Unresectable Stages III-IV Melanoma
NCT01672450 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS-986205) and With or Without CTLA-4 Inhibition (Ipilimumab) in Resectable Stage III or IV Melanoma
NCT04007588 ·Status: WITHDRAWN ·Phase: PHASE2
-
Trial of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated Metastatic Uveal Melanoma
NCT02626962 ·Status: COMPLETED ·Phase: PHASE2
-
Observational Study of Nivolumab Monotherapy or in Combination With Ipilimumab in Participants With Advanced Melanoma and in Participants With Adjuvant Nivolumab Therapy
NCT02990611 ·Status: COMPLETED
-
Nivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratified by MHC-II Expression
NCT03724968 ·Status: TERMINATED ·Phase: PHASE2
-
Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma
NCT04099251 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma
NCT02388906 ·Status: COMPLETED ·Phase: PHASE3
-
Duvelisib in Combination With Nivolumab in Patients With Advanced Unresectable Melanoma
NCT04688658 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Neoadjuvant Trial of Nivolumab in Combination With HF10 Oncolytic Viral Therapy in Resectable Stage IIIB, IIIC, IVM1a Melanoma
NCT03259425 ·Status: TERMINATED ·Phase: PHASE2
-
An Investigational Immuno-therapy Study of BMS-986205 Combined With Nivolumab, Compared to Nivolumab by Itself, in Patients With Advanced Melanoma
NCT03329846 ·Status: COMPLETED ·Phase: PHASE3
-
IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients
NCT04562129 ·Status: RECRUITING ·Phase: PHASE2
-
A Single-Arm, Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) for Subjects With Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma Progressing Post Prior Treatment Containing an Anti-CTLA4 Monoclonal Antibody (CheckMate 172)
NCT02156804 ·Status: COMPLETED ·Phase: PHASE2
-
IPI-Biotherapy for Patients Previously Treated With Cytotoxic Drugs With Metastatic Melanoma
NCT01409187 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064)
NCT01783938 ·Status: COMPLETED ·Phase: PHASE2
-
Neoadjuvant Combination Therapy With Ipilimumab and HighDose IFN-α2b for Melanoma
NCT01608594 ·Status: COMPLETED ·Phase: PHASE1
-
Real-world Outcomes Among Patients With Melanoma Treated With Neoadjuvant Nivolumab+Relatlimab or Nivolumab+Ipilimumab
NCT07091695 ·Status: COMPLETED
-
An Investigational Immuno-therapy Study of Nivolumab Combined With Ipilimumab Compared to Nivolumab by Itself After Complete Surgical Removal of Stage IIIb/c/d or Stage IV Melanoma
NCT03068455 ·Status: COMPLETED ·Phase: PHASE3
-
Adoptive Tumor-infiltrating Lymphocyte Transfer With Nivolumab for Melanoma
NCT04165967 ·Status: COMPLETED ·Phase: PHASE1